Certificate in terms of Regulation 74(5) of the SEBI (Depositories & Participants) Regulations, 2018 for the Quarter and Financial Year ended March 31, 2026, issued to Novartis India Limited ....
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India has submitted a compliance certificate under SEBI Regulation 74(5) for Q4 and FY 2025-26 ended March 31, 2026. This is a routine regulatory filing confirming that the company has received and processed share dematerialization/rematerialization requests from shareholders during the period. The filing verifies that share certificates were duly issued or cancelled as per SEBI guidelines. Note: The actual detailed document content was not accessible due to a BSE page error, so specific numbers or certificate details could not be extracted.
This is a standard SEBI-mandated compliance filing with no direct impact on share price or shareholder value. It simply confirms the company processed share transfer documentation correctly during Q4 FY26.